Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong.
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before…
23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a number of additional clinicallytranslatable drug combinations…